Innate Pharma, a commercial-stage French biotech developing antibody therapies for cancer, raised $69 million by offering 12.5 million shares at $5.50 (€4.97), a 13% discount to its prior closing price on the Euronext Paris (€5.71; ticker IPH). Innate originally filed to offer 10.7 million shares at $7.50 per share. Innate Pharma plans to list on the Nasdaq under the symbol IPHA. Citi, SVB Leerink and Evercore ISI acted as lead managers on the deal.
